Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
BKM-120 is a drug that may slow the growth of cancer cells. This drug has been used in
laboratory experiments and information from those research studies suggests that this drug
may help to slow the growth of renal cancer cells. In this research study, the investigators
are testing the safety to BKM-120 at different dose levels. The investigators will also be
studying how well tolerated BKM-120 is, and how effective BKM-120 can be in the treatment of
kidney cancer.